Supernus Pharmaceuticals (SUPN) Other Non-Current Assets (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Other Non-Current Assets data on file, last reported at $56.5 million in Q1 2026.

• On a quarterly basis, Other Non-Current Assets changed N/A year-over-year to $56.5 million in Q1 2026; TTM through Mar 2026 was $56.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.4 million, down 95.4% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $56.5 million, up from $1.4 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for SUPN reached as high as $403.8 million in Q1 2023 and fell as low as $1.4 million in Q3 2025.
• Historically, Other Non-Current Assets has averaged $60.8 million across 5 years, with a median of $38.7 million in 2023.
• Across the five-year window, Other Non-Current Assets surged 724.23% in 2023 and sank 95.4% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $39.8 million in 2022, then dropped by 2.47% to $38.8 million in 2023, then fell by 18.79% to $31.5 million in 2024, then sank by 95.4% to $1.4 million in 2025, then jumped by 3793.31% to $56.5 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $56.5 million in Q1 2026, $1.4 million in Q4 2025, and $1.4 million in Q3 2025.